Linde plc (LIN) Stock Week Ahead: Latest News, Analyst Forecasts and Key Catalysts for Dec 22–26, 2025

Linde plc (LIN) Stock Week Ahead: Latest News, Analyst Forecasts and Key Catalysts for Dec 22–26, 2025

As of Sunday, December 21, 2025, Linde plc (ticker: LIN) enters a holiday-shortened trading week with a familiar setup: macro headlines and interest-rate expectations are likely to drive near-term sentiment, while Linde’s long-term narrative—pricing discipline, contract-backed backlog, and capital returns—continues
Sandisk (SNDK) Stock Week Ahead: AI-Driven NAND Tightness, Analyst Targets, and Key Catalysts for Dec. 22–26, 2025

Sandisk (SNDK) Stock Week Ahead: AI-Driven NAND Tightness, Analyst Targets, and Key Catalysts for Dec. 22–26, 2025

Date: Sunday, December 21, 2025Ticker: Sandisk Corporation (NASDAQ: SNDK) Sandisk stock heads into the final full holiday stretch of 2025 with momentum, volatility, and a growing spotlight from both Wall Street and index investors. The latest available quote shows SNDK
KLA Corporation Stock (KLAC) Week Ahead Outlook: Analyst Upgrades, AI Equipment Forecasts, and What to Watch Dec. 22–26, 2025

KLA Corporation Stock (KLAC) Week Ahead Outlook: Analyst Upgrades, AI Equipment Forecasts, and What to Watch Dec. 22–26, 2025

Updated for the week ahead (Dec. 22–26, 2025). KLA Corporation (NASDAQ: KLAC) enters the Christmas-shortened trading week with momentum from fresh Wall Street upgrades and a strengthening top-down narrative: the AI infrastructure buildout is keeping semiconductor capital spending—especially at the
Amicus Therapeutics (FOLD) Stock Week Ahead: $14.50 BioMarin Buyout Puts the Deal Spread—and New Filings—Front and Center (Dec. 22–26, 2025)

Amicus Therapeutics (FOLD) Stock Week Ahead: $14.50 BioMarin Buyout Puts the Deal Spread—and New Filings—Front and Center (Dec. 22–26, 2025)

As of Sunday, December 21, 2025, Amicus Therapeutics, Inc. (NASDAQ: FOLD) is no longer trading like a “typical biotech story stock.” After BioMarin’s all-cash $14.50-per-share takeover agreement, FOLD has effectively become a deal-driven, merger-arbitrage name—meaning next week’s action is likely
Go toTop